Emerald Advisers, LLC Acadia Pharmaceuticals Inc Transaction History

Emerald Advisers, LLC

$2.36 Billion
Q1 2024

A detailed history of Emerald Advisers, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Emerald Advisers, LLC holds 1,651,124 shares of ACAD stock, worth $26.8 Million. This represents 1.29% of its overall portfolio holdings.

Number of Shares

1,651,124

Previous 1,645,565 0.34%

Holding current value

$26.8 Million

Previous $51.5 Million 40.75%

% of portfolio

1.29%

Previous 2.31%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$17.79 - $30.86 $98,894 - $171,550	5,559 Added 0.34%	1,651,124 $30.5 Million
Q4 2023 Feb 05, 2024	SELL	$20.78 - $31.77 $737,419 - $1.13 Million	-35,487 Reduced 2.11%	1,645,565 $51.5 Million
Q3 2023 Oct 26, 2023	BUY	$20.84 - $33.47 $1.34 Million - $2.15 Million	64,100 Added 3.96%	1,681,052 $35 Million
Q2 2023 Jul 25, 2023	BUY	$17.8 - $25.65 $2.14 Million - $3.09 Million	120,392 Added 8.04%	1,616,952 $38.7 Million
Q1 2023 May 04, 2023	BUY	$16.32 - $20.92 $2.85 Million - $3.65 Million	174,414 Added 13.19%	1,496,560 $28.2 Million

Q4 2022 Feb 03, 2023	SELL	$14.2 - $18.63 $106,216 - $139,352	-7,480 Reduced 0.56%	1,322,146 $21 Million
Q3 2022 Oct 25, 2022	BUY	$14.11 - $18.27 $6.62 Million - $8.57 Million	468,877 Added 54.47%	1,329,626 $21.8 Million
Q2 2022 Jul 29, 2022	BUY	$13.01 - $27.22 $936,863 - $1.96 Million	72,011 Added 9.13%	860,749 $12.1 Million
Q1 2022 Apr 29, 2022	BUY	$20.94 - $27.5 $1.5 Million - $1.96 Million	71,420 Added 9.96%	788,738 $19.1 Million
Q4 2021 Feb 02, 2022	BUY	$16.79 - $27.09 $12 Million - $19.4 Million	717,318 New	717,318 $16.7 Million

Others Institutions Holding ACAD

# of Institutions

299

Shares Held

158M

Call Options Held

1.88M

Put Options Held

688K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.63B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.

Account

Emerald Advisers, LLC Acadia Pharmaceuticals Inc Transaction History